New pill shows promise for tough lung cancer
NCT ID NCT05363280
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 30 times
Summary
This study tests an oral drug called AL8326 in people with advanced small cell lung cancer that has returned or spread after at least one prior treatment. The goal is to find the best dose and see if it can shrink tumors or slow cancer growth. About 36 adults with good performance status are being enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cleveland Clinic
Cleveland, Ohio, 44195, United States
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario Ramón Y Cajal
Madrid, Spain
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Siteman Cancer Center, Washington University
St Louis, Missouri, 63130, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.